RNA Outsourcing

OUTSOURCING ARTICLES

How Informal FDA Feedback Is Quietly Driving RNA Capital Allocation
Subtle FDA signals — especially in pre-IND talks — are quietly shaping RNA investment. Early regulatory feedback on CMC and comparability now drives how investors assess risk and allocate capital.
2026 RNA Investment Landscape: Recent Deals, IPOs, And Venture Trends
As RNA investing matures, capital is flowing toward delivery, durability, and regulatory credibility. This column breaks down the deals, IPO signals, and venture theses shaping RNA’s 2026 winners—and why.
A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026?
In 2026, advanced therapies diverge: winners pair proven biology with scalable manufacturing, delivery, and workflow fit, while others advance more slowly under operational and economic limits.
Beyond The Hype: How 2025's Successes & Realities Will Shape mRNA In 2026
Here, in part two of this multi-part series, we hear from Melissa Bonner, CSO of nChroma Bio and Andy Geall, CDO of Replicate Biosciences, who call attention to several developments of the past year they’ve been watching and how they see these developments informing our conversations about and work with mRNA in 2026 and beyond.
Four Reasons You Should Choose Lyophilization for Your Next Project
Lyophilization ensures product stability, extends shelf life, supports sensitive formulations, and simplifies storage and transport, making it a critical choice for modern drug development projects.
Trends In Oligo Scale-Up & Delivery & How They're Impacting Manufacturing
Here, a panel of experts at the RNA Leaders Conference gives a fantastic overview of where we are today and why, as one expert so nicely put it, “This is one of the most fun times to be an oligo scientist or chemist.”

OUTSOURCING VIDEOS

Must-Have CDMO Capabilities And MSA Make-Or-Breaks For mRNA-LNP Outsourcing

Three Advancing RNA Live panelists share their greatest needs in outsourcing partnerships for mRNA/RNA-LNP products and where sponsors should be the most prescriptive when drafting an MSA with an outsourcing partner.

Scale-Up And Production Of Key Lipids Used In mRNA Delivery Systems

Discover key strategies for overcoming challenges in the industrial-scale production of ionizable and PEG lipids to optimize mRNA vaccine formulation and address critical manufacturing requirements.

Addressing Industry Challenges In mRNA Product Commercialization

While the speed of production and flexibility of mRNA are appealing, several industry challenges must still be addressed to realize the full potential and further expand its use.

Our Experience Creates Reliable Results

Hear from inSeption Group clients as they share their experiences, recount their journeys and highlight the exceptional service and support they received.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

Step-By-Step Guide To Tech Transfer Preparation And Execution

How does a sponsor accurately transfer detailed knowledge about its product composition, development, and current manufacturing processes to its CDMO?
Is Your Biologics CDMO Transparent?

Transparency and collaboration with a CDMO are vital for reducing risk and protecting IP. Discover four essential practices, from clear communication to IP safeguards, that help build trust.
Why Bioanalysis Needs To Break Free From Manual Bottlenecks

Bioanalysis remains one of the most persistent bottlenecks in drug development, with CROs displaying inefficiencies that are no longer operational nuisances but strategic liabilities.
Avoiding The Pitfalls Of LNPs And Complex Formulations

Explore the necessary components of a smooth tech transfer for LNP-based drugs, including the variables that impact LNP formulation and the outsourcing strategies needed to avoid common pitfalls.
Choosing The Best mRNA Manufacturing Strategy

Choosing the right mRNA manufacturing model can define your success. Learn how to weigh control, cost, and flexibility to build a strategy that supports innovation and long-term growth.
Enabling CDMOs To Focus On Core Priorities

Explore innovative solutions for CDMO's striving to remain competitive as the biopharmaceutical market grows and evolves.
Understanding Technology Transfer In Pharmaceutical Contract Manufacturing

Technology transfer is a crucial process in the pharmaceutical industry, ensuring drugs developed in labs can be manufactured consistently at scale.

More Outsourcing Resources

OUTSOURCING ARTICLES

OUTSOURCING VIDEOS

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

OUTSOURCING SOLUTIONS